RedHill Biopharma Announces New US Patent

in an Initial Study is Planned to Commence Q2/2013; Multi-Site Initiation Process is Underway; Newly Issued Patent Expires no Earlier Than 2029

Additional Planned and Required Studies, Which Include a Second Phase III Crohn’s Disease Trial in Europe and Other , Are Under Preparation as Part of ’s Development and

RedHill Biopharma Ltd. RDHL 0.00% (tase:RDHL) (the “Company” or “RedHill Biopharma”), an emerging Israeli primarily on the development and acquisition of late clinical-stage, patent-protected, new formulations and combinations of existing drugs, reported today the issuance of a new U.S. patent and that a multi-site initiation process is underway in the U.S., and Israel for a first multi-center, randomized, double-blind, placebo-controlled, parallel group III study (the “MAP US Study”) to assess the efficacy and safety of fixed- RHB-104 in subjects with moderately to severely active Crohn’s disease. The MAP US Study will be conducted under an Investigational New Drug (IND) application amended in August 2012 and recruitment is planned to commence in the second quarter of 2013.

RedHill Biopharma Announces Issuance of New US Patent and Provides
MarketWatch (press release)
In addition to the MAP US Study which is designed to provide insights into safety and efficacy of RHB-104 and initial assessment of the role of MAP in Crohn’s disease, the Company is planning and preparing for a Phase III clinical trial in Europe with and more »

Leave a Reply